Updated August 2026
Pinealon Dosage: Human Oral and IM Research, Protocol, and Math
Research note: Pinealon has no standardized US prescribing dose. This page documents doses from patents, small human reports, secondary reviews, animal work, and research communities — it does not convert those reports into treatment advice. The complete protocol below is an investigator-run study framework requiring ethics approval and regulated manufacturing — not a self-treatment plan.
Most consistently reported human oral exposure: 0.2–0.4 mg/day. A 75-person elderly cohort reportedly used 100 µg twice daily for 14 days; a secondary account of a 72-person post-TBI series reports 0.2 mg twice daily for 20–30 days. A 15-day athlete study used a variable oral schedule totaling 2 mg.
European patent IM example: 1 µg, 10 µg, or 5 mg once daily for 10 days assigned by injury severity — not a credible dose-finding study. Subgroup sizes were undisclosed and outcomes were pooled.
Current SC schedules (100–300 µg, 1–3 mg, or 5–10 mg daily) disagree by ~100-fold and are community conventions. No direct human SC or intranasal PK study was located. Pinealon (EDR) is not Epitalon (AEDG).
Pinealon dosage in 30 seconds
| Question | Research summary |
|---|---|
| Identity | EDR · Glu-Asp-Arg · ≈418.407 g/mol free peptide |
| ≠ | Epitalon (AEDG) · pineal extracts · AC-5 complex by default |
| Best-described oral | 0.2 mg BID × 20–30 days (secondary TBI report) |
| Other oral | 0.1 mg BID × 14 days; athlete 2.0 mg / 15 days |
| Patent IM | 1 µg · 10 µg · or 5 mg once daily × 10 days |
| Validated SC / IN | Not located |
| Human weight-based dose | Not established |
| Human PK | Not established |
What is Pinealon?
Pinealon is the short synthetic peptide L-glutamyl-L-aspartyl-L-arginine (EDR). It was developed in a cortex-associated peptide-bioregulator program. It is not a pineal hormone, melatonin analogue, or pineal-gland extract.
The name is frequently confused with Epitalon (Ala-Glu-Asp-Gly). Different sequences and dosing literature. Free-peptide formula C15H26N6O8, MW 418.407, CAS 175175-23-2, PubChem CID 10273502.
Identity gate
Confirm synthetic EDR — not Epitalon, AC-5 complex, or gross capsule mass
Matches Pinealon identity on this page
Tripeptide H-Glu-Asp-Arg-OH (~418.407 g/mol free peptide). Confirm sequence, chirality, assay-corrected active mass, counterion/water, and (for parenteral research) sterility/endotoxin.
Product identity is not always consistent
| Label | What it may mean | Treat as pure EDR? |
|---|---|---|
| Synthetic EDR | Chemically synthesized Glu-Asp-Arg | Only if assay-verified |
| Patent material | Acetate ion pair · ~6% moisture example | Correct for assay/water |
| Historical 100 µg capsule | 0.1 mg active per capsule described | Need batch specification |
| AC-5 complex capsule/liquid | Peptide complex + excipients | Not automatically |
| Online 5–20 mg vial | Often lyophilized “research” EDR | Nominal fill ≠ identity/sterility |
Current research and regulatory status
Pinealon has no standardized US prescribing label. A patent protects claimed IP; it does not validate efficacy or prove modern products match tested material. Current Russian product pages often describe capsules as a dietary supplement or peptide complex.
A ClinicalTrials.gov search for Pinealon / Glu-Asp-Arg did not locate a clearly registered interventional study as of August 2026. Existing human reports fall well short of a modern dose-development program.
Pinealon dosages reported in human research
Only direct or secondary accounts of administered Pinealon are summarized below.
Human evidence status
Oral microgram reports + one severity-confounded patent IM example
- Standardized US prescribing dose
- None
- Best-described oral amount
- 0.2 mg BID × 20–30 days (secondary TBI report)
- Other repeated oral amount
- 0.1 mg BID × 14 days
- Athlete oral course
- Variable 0.1–0.2 mg/day × 15 days (2.0 mg cumulative)
- Patent human IM amounts
- 1 µg, 10 µg, or 5 mg once daily × 10 days
- Validated human SC / IN
- Not located
- Human PK / bioavailability
- Not established
- ClinicalTrials.gov interventional study
- None clearly registered (Aug 2026)
- Long-term safety
- Poorly characterized
Human reports at a glance
| Source | Amount | Route / duration | Main limit |
|---|---|---|---|
| EP patent Example 8 | 1 µg · 10 µg · or 5 mg | IM once daily × 10 days | Severity-confounded; pooled outcomes |
| TBI series (secondary review) | 0.2 mg per dose | Oral BID × 20–30 days | Primary full report not located |
| Balashova et al., 2008 | 0.1 mg per dose | Oral BID × 14 days | Limited design/safety detail |
| Lysenko et al., 2012 | 0.1–0.2 mg/day variable | Oral × 15 days (2.0 mg total) | Uncontrolled athlete before/after |
| Truck-driver study, 2012 | Capsule + Vesugen | Oral BID × 30 days | Combination; effect not isolable |
The patent’s 5 mg IM arm is 500× the intermediate and 5,000× the mild amount. Because dose followed baseline severity, the example cannot separate dose response from severity-group differences.
Reported research dosage landscape
The 1 µg–5 mg IM and 0.1–10 mg community SC intervals describe discordant reports — not a validated therapeutic range. Combining endpoints into one “standard dose” would be misleading.
Evidence split
Published / patent human reports vs current web conventions
Human clinical / experimental reports
Low evidence · incomplete methods
- Oral amount
- 0.1–0.2 mg per administration
- Oral daily
- 0.1–0.4 mg/day · 14–30 days
- IM amount
- 1 µg, 10 µg, or 5 mg × 10 days (patent)
- SC / IN
- No direct human schedule located
- Dose response
- Not established
- PK confirmation
- None
Current anecdotal / commercial
Conventions · up to ~100× disagreement
- Oral products
- Capsules / AC-5 complex — active EDR often unclear
- Low SC pages
- 100–300 µg daily or EOD
- Mid SC pages
- 1–3 mg daily × ~10 days
- High SC pages
- 5–10 mg daily (often vial-size arithmetic)
- Intranasal pages
- 100–400 µg — no human PK
- Primary source
- None located for modern injection schedules
Oral exposure arithmetic
Historical capsules were often described as 100 µg active per capsule. Course totals depend on morning/evening timing and days — use assay-corrected EDR, not gross capsule or AC-5 complex mass.
Oral exposure math
Assay-corrected EDR course totals — not AC-5 or gross capsule mass
Daily exposure
0.4 mg
Course length
28 days
Cumulative
11.200000000000001 mg
Best-described oral regimen (0.4 mg/day; 20–30 day course) Documented exposure ≠ proven therapeutic dose.
Complete evidence-anchored research protocol (oral EDR replication)
Most defensible next human study: placebo-controlled oral replication of the best-described regimen using assay-confirmed synthetic EDR — not adoption of an online SC/IN convention.
Proposed PINE-1 exposure: 0.2 mg assay-corrected L-EDR orally twice daily for 28 days (0.4 mg/day; 11.2 mg cumulative) in adults with persistent cognitive symptoms after mild/moderate TBI. Primary objective: safety/tolerability; secondary: PK and feasibility.
PINE-1 research framework
0.2 mg oral BID × 28 days · assay-corrected synthetic EDR · vs placebo
1–28
0.2 mg EDR BID (0.4 mg/day · 11.2 mg cumulative)
Randomized vs placebo; intensive PK days 1 & 28; sentinel DSMB after day 7
Investigator-initiated design only — ethics approval, GMP product, and DSMB required. Not a home or clinic “stack” schedule.
No within-participant escalation, loading dose, or taper — those features are not supported by the human literature. First modern study should not jump to SC or intranasal without matching human PK evidence.
Concentration and reconstitution math
The proposed human protocol uses manufactured oral capsules and requires no reconstitution. Lab/investigational-pharmacy arithmetic below does not validate SC use or provide a home-injection procedure.
Pharmacy arithmetic
Lab / investigational volume examples — does not validate SC use
Nominal vial
Diluent volume
Target amount
Withdrawal volume
0.040 mL
5.0 mg/mL · ≈ 4.0 U-100 units · 200 µg target
Volumes under ~0.05 mL are often unreliable with common syringes — use validated serial dilution in a qualified lab/pharmacy.
Patent IM example reconstructed concentrations
| Patent amount in 1 mL | Concentration |
|---|---|
| 1 µg | 0.001 mg/mL |
| 10 µg | 0.010 mg/mL |
| 5 mg | 5 mg/mL |
Using 418.407 g/mol: 100 µg ≈ 0.239 µmol; 200 µg ≈ 0.478 µmol; 5 mg ≈ 11.95 µmol. Correct for salt/hydrate using the lot assay.
Animal and laboratory research dosage
Patent toxicology used single IM mouse doses up to 5 mg/kg and subacute/chronic IM rodent/guinea-pig regimens at 1 µg/kg–1 mg/kg. Disease models include 10 µg/kg IM trauma paradigms, fixed 1 µg IP hypoxia work, 10 µg/kg IP prenatal hyperhomocysteinemia, 50–200 ng/kg diabetic-rat learning, and 400 µg/kg IP × 2 months in 5xFAD mice.
Animal mg/kg amounts and cell concentrations (ng/mL or nM) must not be copied into a human schedule.
How Pinealon may work
Proposed themes include reduced ROS in stressed cells, altered ERK1/2 timing, cell-cycle/apoptosis processes, NMDA-subunit expression in animals, dendritic-spine/LTP preservation in 5xFAD mice, and modeled DNA-promoter binding.
Direct peptide–DNA binding, GDF11 regulation, “epigenetic rejuvenation,” and human brain target engagement have not been confirmed in a controlled human dosing study. No validated human bioavailability, half-life, or brain-exposure study was located.
Potential benefits: what has and has not been shown
Claim vs evidence
| Claim | Current conclusion |
|---|---|
| Oral microgram courses documented in humans | Yes — short, incompletely reported studies |
| Effective TBI / cognition dose | Not established |
| SC or intranasal clinical dose | Not established |
| Anti-aging / lifespan benefit | Not established |
| Alzheimer’s / Parkinson’s prevention | Not established |
| Athletic performance enhancement | Uncontrolled athlete study only |
Pinealon safety and side effects
Short oral studies and the patent example did not describe a clear recurring adverse-event pattern — but sparse reporting is not proof of safety. Patent toxicology reports no major toxicity at tested animal doses.
The 2015 polymorbidity report found pro-oxidant chemiluminescence and reduced circulating CD34+ markers after Pinealon or Vesugen, with uncertain clinical meaning.
Safety monitoring
Sparse AE reporting — not a “no side effects” conclusion
- Human AE incidence
- Not adequately characterized — short reports lack modern solicited AE tables and follow-up
- 2015 signal
- Polymorbidity report: pro-oxidant chemiluminescence and reduced circulating CD34+ markers after Pinealon or Vesugen — clinical meaning uncertain
- Neurologic context
- Intended populations may already have headache, sleep/mood symptoms, or seizure risk — monitor carefully in research
- Product / injection risks
- Identity mismatch (AC-5 vs pure EDR); sterile/endotoxin harm if injected; hypersensitivity to peptide or excipients
Product quality and storage
No universal beyond-use date after reconstitution is supported by a public clinical stability study. Vendor “28 days refrigerated” claims are not substitutes for stability-indicating assay and sterility programs.
The patent reports acetate as an ion pair, 98.01% HPLC area, and 6% moisture for its example material — identify whether a milligram value is gross mass or assay-corrected EDR equivalent.
Common claims vs evidence
Claim checker
Common Pinealon claims vs the evidence record
There is a standard Pinealon dose
False
No established standard. Oral reports use 0.1–0.2 mg per dose; the patent used three severity-assigned IM amounts.
Pinealon dosage evidence ladder
Dosage evidence ladder
Pinealon dosing is poorly established
| Level | What exists | Confidence |
|---|---|---|
| Established clinical use | None | None |
| Modern phase 1 / dose-ranging RCT | None located | None |
| Human oral reports | Small / incompletely reported studies (0.1–0.2 mg) | Low |
| Human IM dosing | One patent example (1 µg / 10 µg / 5 mg) | Very low |
| Human SC / intranasal | No direct study located | Insufficient |
| Animal research | Trauma, hypoxia, diabetes, 5xFAD models | Preclinical |
| Community protocols | 0.1–10 mg SC and IN conventions | Anecdotal |
Pinealon dosing is poorly established. Oral microgram reports and a severity-confounded patent IM example do not support modern high-milligram SC schedules as clinical protocols.
Sports and anti-doping considerations
Pinealon is not named individually on the 2026 WADA Prohibited List, but section S0 may cover non-approved pharmacologic substances. Competitive athletes should obtain written guidance from their anti-doping organization before exposure.
Bottom line
There is no established Pinealon dose. Human evidence mainly documents oral 0.1–0.2 mg per administration, a secondary 0.2 mg BID × 20–30 days account, and patent IM amounts of 1 µg / 10 µg / 5 mg for ten days.
Current SC and intranasal protocols vary by up to 100-fold without matching human PK. The most informative next step is a regulated, placebo-controlled oral replication with assay-confirmed synthetic EDR, intensive PK, and modern neurologic/hematologic monitoring.
EDR ≠ Epitalon. Gross capsule / AC-5 complex mass ≠ assay-corrected Pinealon. Community 5–10 mg SC schedules are not clinical-trial protocols.
Frequently asked questions
What is the standard Pinealon dose?
There is no established standard dose. Human reports used several oral schedules and one patent used three very different fixed IM amounts.
What oral Pinealon dose has been studied?
Reported schedules include 0.1 mg twice daily for 14 days, a variable 0.1–0.2 mg/day athlete course for 15 days, and 0.2 mg twice daily for 20–30 days in a secondary TBI account.
What injection dose has been studied in people?
One European patent example reports 1 µg, 10 µg, or 5 mg IM once daily for ten days, assigned by injury severity. No modern direct human SC study was located.
Is 5–10 mg subcutaneous Pinealon a clinical-trial protocol?
No. It is a current community convention. Some commercial pages link the amount to common 10 mg vial sizes rather than dose-finding studies.
Has intranasal Pinealon been studied in humans?
No direct human intranasal PK, safety, or dose-finding study was located. Online 100–400 µg schedules are insufficiently sourced.
Is Pinealon dosed by body weight?
Not in validated human research. The patent’s 0.01–100 µg/kg claim should not be treated as a personal dosing formula.
Is Pinealon the same as Epitalon?
No. Pinealon is EDR (Glu-Asp-Arg); Epitalon is AEDG (Ala-Glu-Asp-Gly).
Does Pinealon treat traumatic brain injury?
There are small and incompletely reported post-TBI human studies, but they do not establish clinical efficacy or replace evidence-based rehabilitation and medical care.
Does Pinealon prevent Alzheimer’s or Parkinson’s disease?
No. A 5xFAD mouse study and gene-expression hypotheses are not proof of prevention or treatment in people.
Can Pinealon be stacked with other peptides?
No controlled human study validates a Pinealon stack. Combining investigational products increases uncertainty and prevents attribution of benefits or harms.
References
PubChem
Glu-Asp-Arg, CID 10273502Chemical identity and molecular weight.
European Patent Office
EP 2 024 388 B1 — peptide substance stimulating CNS neuron regenerationIncludes human IM Example 8 and animal toxicology examples.
Khavinson VK et al.
GDF11 Protein as a Geroprotector — review containing TBI regimen accountSecondary source for 0.2 mg BID oral series.
Balashova SN et al.
Peptide bioregulators in elderly psychoemotional disorders0.1 mg oral BID × 14 days abstract.
Lysenko AV et al.
Influence of Pinealon on reserve capabilities of athletes15-day oral schedule totaling 2.0 mg.
Meshchaninov VN et al.
Synthetic peptides in polymorbidity2015 pro-oxidant / CD34+ signal report.
Khavinson V et al.
Neuroprotective effects of tripeptides in a mouse Alzheimer model5xFAD · 400 µg/kg IP · preclinical.
WADA
2026 Prohibited ListS0 non-approved substance considerations.